Clinical Implication of Atrial Fibrillation Detection Using Wearable Device in Patients With Cryptogenic Stroke (CANDLE-AF)
Atrial Fibrillation, Ischemic Stroke, Transient Ischemic Attack
About this trial
This is an interventional screening trial for Atrial Fibrillation focused on measuring Atrial fibrillation, Ischemic Stroke, Transient Ischemic Attack
Eligibility Criteria
Inclusion Criteria: Newly diagnosed brain infarction No history and diagnosis of atrial fibrillation at the time of admission Rejected implantable loop recorder Informed consent Exclusion Criteria: Cannot use KardiaMobile system alone or with the help of others
Sites / Locations
- Yonsei University Health System, Yongin Severance Hospital
- Ewha Womans University Seoul HospitalRecruiting
- Hanyang University Seoul HospitalRecruiting
- Ewha Womans University Mokdong HospitalRecruiting
- Daegu Catholic University Medical CenterRecruiting
- Gachon University Gil HospitalRecruiting
- Kyung Hee University HospitalRecruiting
- Yonsei University Health System, Severance HospitalRecruiting
- Korea University Guro HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Experimental
Experimental
Conventional Holter Monitoring Group
Discontinuous Monitoring Group
Single-lead Continuous Patch Group
Holter monitoring is performed for 24 hours each at 1, 3, and 12 months after the diagnosis of stroke, and if atrial fibrillation is detected, the antiplatelet drug is changed to an anticoagulant.
Discontinuous ECG monitoring by finger contact is performed 3 times every day for 12 months after a stroke diagnosis. If atrial fibrillation is detected, the antiplatelet drug is changed to an anticoagulant.
Continuous 72 hours of ECG monitoring by a single-lead patch is performed at a week and 1, 3, 6, 12 months after a stroke diagnosis. If atrial fibrillation is detected, the antiplatelet drug is changed to an anticoagulant.